A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

Stopped early · Phase 1/Phase 2

Conditions studied: Renal Cell Carcinoma

In brief

This study is being conducted to determine the Maximum Tolerated Dose (MTD) and efficacy of the combined treatment of Temsirolimus and Sunitinib for the treatment of Advanced Kidney Cancer

Key facts

Study ID

NCT00417677

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

124

Starts

2007-03-01

Expected to finish

2007-05-01

Last updated by the study team

2007-12-28

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Study site — Baltimore, Maryland, United States
• Study site — Boston, Massachusetts, United States
• Study site — New York, New York, United States
• Study site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.